AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04362605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Negative Pressure Therapy
Description: In patients with suspected insufficiency of the esophagojejunostomy first an index endoscopy under general anesthesia with endotracheal intubation was indicated. Standard gastroscopes with outer diameter of 9.8mm were used with carbon dioxide insufflation.~Definition of a anastomotic leak were endoscopic or radiological dehiscences at the esophagojejunostomy with extravasation of fluids and gas. In cases of insufficiencies start of endoluminal ENPT were indicated.~Decision criteria for placement of OPD or OFD were the defect size, radiological findings and clinical situation of the patient. A CT scan in patients with suspected EJAL was done in all cases.~For endoluminal ENPT, the open-pore drainage system is placed within the lumen of the digestive tract at the entrance to the cavity.
Study NCT02774161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Tomography
Description: Undergo B-mode ultrasound imaging
Study NCT03681704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuangQi Decoction
Description: HuangQi Decoction 150ml twice a day for 24 weeks
Study NCT03681704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HuangQi Decoction placebo
Description: traditional Chinese medicine placebo mimic HuangQi Decoction 150ml twice a day for 24 weeks
Study NCT02306486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: with 0,5% oxalic acid (Desenssiv SSWhite)
Description: with 0,5% oxalic acid (Desenssiv SSWhite) , desensitizer for sensivity cervical lesions on tooth
Study NCT02954640 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: Additional blood sampling for the realization of the test on the gene panel
Study NCT00551811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be intended to be administered orally.
Study NCT03011502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples collection of blood and feces
Study NCT02808637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Pressure
Description: First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered in accordance with the conventional injection technique.
Study NCT02808637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Injection without Aspiration
Description: First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using rapid injection without aspiration technique.
Study NCT02808637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Pressure + Rapid Injection without Aspiration
Description: First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered by using the rapid injection without aspiration technique.
Study NCT02808637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using the conventional injection technique.
Study NCT03168789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tension Tamer (TT)
Description: Tension Tamer is an app that provides training and motivation for breathing awareness meditation (BAM). The app also tracks heart rate values during each session by placing a finger tip over the rear camera.
Study NCT03168789 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle education program (SPCTL)
Description: SPCTL group will use Runkeeper app to log physical activity. They will also receive text messages with short healthy lifestyle tips, and links to media with pamphlets or videos with more in-depth information.
Study NCT01344512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Description: Bloods sampling on patient treated with Ceftazidime between 48 hours and 4 days after beginning of treatment.
Study NCT01344512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Bloods sampling on patient treated with Ciprofloxacin between 48 hours and 4 days after beginning of treatment.
Study NCT01344512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Bloods sampling on patient treated with Voriconazole between 48 hours and 4 days after beginning of treatment.
Study NCT00451100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Subjects received a bolus dose of 0.6 mg/kg rocuronium. After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg Org 25969 was to be administered
Study NCT00451100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: Subjects received a bolus dose of 0.15 mg/kg cisatracurium. After the last dose of cisatracurium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered. In accordance to the labeling of neostigmine, a maximum of 5 mg neostigmine was to be administered
Study NCT02336178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benefix
Description: Subjects will be treated by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.~The treatment duration is approximately 6 months (±7 days) or approximately 50 Exposure Days (EDs) (±5 EDs) (see protocol definition on EDs) whichever occurs first.
Study NCT02950324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Patients in the intervention, 'Prehabilitation', arm of the study will be enrolled into a multimodal programme that involves 15 weeks of exercise, nutritional support and psychological prehabilitation in the form of 'Medical Coaching'. This will take place during neo-adjuvant treatment prior to oesophagectomy or gastrectomy for cancer.
Study NCT02950324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients in the 'standard care' arm of the study will not receive the study intervention. The patients will continue to be offered theatients in this arm of the study will not receive the study intervention. The patients will continue to be offered the standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care.
Study NCT00294554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Active memantine and placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
Study NCT00294554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
Study NCT03902977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quilting
Description: After mastectomies or ALND dissections using standard technique for wound closure multiple sutures (monocryl 3.0) every 3 to 4 cm in the site of the mastectomy (1 or 2 rows) or in the dissected axilla.Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision
Study NCT03902977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional suture
Description: After mastectomies or ALND dissections standard technique for wound closure. Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision
Study NCT03053817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Interval training will be performed for 21 minutes including a 3 minute warm-up and cool-down period. The interval program will be 15 minutes at 65-75% of maximal heart rate with 30 sec. bursts of exercise to 80-85%; intervals. Resistance training will be done as a circuit and will make use of weight machines and functional exercises. Resistance will be done in 2 sets of 15 repetitions and will last 24 minutes. The work load of the program is calibrated and is conducted at a specified rhythm. All exercise sessions will be supervised.
Study NCT00545454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR150106
Study NCT00545454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT04248426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-2173
Description: ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.
Study NCT04248426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATI-2173 Placebo
Description: ATI-2173 Placebo is used as an inactive comparator to ATI-2173. It will be dosed as a capsule by mouth.
Study NCT02484118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis blood flow
Description: The impact of blood flow rates of 320 ml/m and 380 ml/m will be compared to determine any impact on hemodialysis urea clearance
Study NCT04057326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oryz-Aspergillus Enzyme and Pancreatin Tablet
Description: 2 tablets/time, 3 times daily,Oral Administration.
Study NCT04057326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets/time, 3 times daily,Oral Administration.
Study NCT03918837 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Participants will undergo sham rTMS for five days with two daily fifteen minutes rTMS sessions.
Study NCT03918837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: Participants will undergo active rTMS for five days with two daily fifteen minutes rTMS sessions.
Study NCT03586492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CZT SPECT acquisition
Description: CZT SPECT acquisition, with dynamic stress and rest acquisitions to calculate CFR If pathological, coronarography with FFR measurement if necessary In case of intermediate coronary stenosis with medical treatment, SPECT CFR evaluation after one year of treatment
Study NCT01815346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: One group receives acupuncture 2 times a week for 6 weeks.~One group receives acupuncture 3 times a week for 4 weeks.~Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
Study NCT01815346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Three questionnaires completed at baseline, midpoint, and four weeks after completion of acupuncture treatment.
Study NCT01815346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Function and Balance Tests
Description: Tests completed at baseline, midpoint, and four weeks after completion of acupuncture treatment. These tests should take about 20 minutes to complete.
Study NCT01831388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing techniques
Description: During all practice sessions, patients are seated in a chair, where they are guided through a set routine of various breathing techniques (detailed in Appendix A). No yoga poses are involved. There is no demand on the patient's physical condition and no risk of injury. The breath training program, with patients seated throughout, includes:~- an initial teaching session (approximately 30-minute) at main campus by an MSKCC Integrative Medicine Service yoga-breathing instructor; - twice daily,breathing exercises (each approximately 15-minute) for 6 weeks practiced by patients at home with supplied recorded audio instructions; - and weekly follow-up phone calls by research staff (+/- 3 days from day 7 of each week) to identify and manage problems and to determine compliance.
Study NCT01831388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Administered Baseline and Transition Dyspnea Indexes
Description: Patients are asked to complete baseline SAC-BDI/TDI questionnaires at the pulmonary clinic. Patients will return to the pulmonary clinic at about week 6 for SAC-BDI/TDI and tests, and to return the diary recording their home exercises. Resting and post-6MWT pulse oximetry, and Hospital Anxiety and Depression Scale (HADS) will be evaluated as well.
Study NCT05935124 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: WLE first, then B-NBI
Study NCT01896167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxia
Description: Inhalation of hypoxic air (8-12% oxygen content)
Study NCT01896167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation of atmospheric air
Study NCT02515370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Friends for Life Circles (FLCs).
Description: The intervention 'Friends for Life Circles (FLCs) will build dynamic peer group support in the community aimed at supporting maternal adherence to appointment keeping and taking lifetime antiretroviral drugs
Study NCT01081652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronised Progesterone
Description: Micronised progesterone administered intravaginally once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
Study NCT01081652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Progesterone 60 mg administered intramuscular once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
Study NCT03469037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow with an inspired fraction of oxygen of 100%
Description: Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 100%
Study NCT03469037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow with an inspired fraction of oxygen of 21%
Description: Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 21%
Study NCT02396121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement : Renutryl® Booster
Study NCT01281124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given subcutaneously
Study NCT01281124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01281124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00744497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00744497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Study NCT00744497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT00744497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Study NCT00744497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study NCT00744497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Study NCT03109964 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar coagulation forceps (ETHICON inc.)
Description: Hemostasis of the base of the ovarian cyst by utilization of a bipolar coagulation device.
Study NCT03109964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SURGIFLO hemostatic matrix (ETHICON inc.)
Description: Hemostasis of the base of the ovarian cyst by utilization of a an absorbable gelatin based matrix known as SURGIFLO.
Study NCT01116986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling before quit attempt
Description: Participants randomized to this condition will have 20-minute in-person counseling sessions 1 and 3 weeks before their target quit day and a 20-minute phone counseling session 2 weeks before their target quit day. In the in-person counseling session, the case manager will address issues such as smoking reduction, withdrawal coping, environmental restrictions on smoking, intra-treatment social support, autonomous motivation, and practice quit attempts. Participants will be asked to engage in two practice quit attempts. These attempts will each last 8 hours and will be assigned (in collaboration with the smoker) to occur on one weekend day and one weekday the second and third weeks after the quit day.
Study NCT01116986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal In-person counseling during quit attempt
Description: Participants randomized to minimal in-person counseling will receive one 3-minute in-person session occurring one week before their target quit day. The clinician will also inform the participant of the sort of phone counseling follow-up that s/he will receive in 1 and 2 weeks after their quit date. (This resembles the real-world situation in which the clinician discusses the sort of follow-up intervention a patient will receive.)
Study NCT01116986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive in-person counseling during the quit attempt
Description: Participants randomized to intensive in-person counseling will receive three 20-minute face-to-face counseling sessions: one during the week before the target quit day, one on the target quit day and one during the week after the target quite day. The counseling will include intra-treatment social support and skill-based competence intervention components.
Study NCT04017728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Percutaneous Vertebroplasty
Description: The cement is injected into the bone metastases directly.
Study NCT04017728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Vertebroplasty with Rotary Cutter
Description: The rotary cutter is applied before the cement injection. Then, the cement is injected with lower pressure.
Study NCT05390983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy with stent removal
Description: Standard carotid endarterectomy will be extended with the stent removal
Study NCT05390983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid endarterectomy with stent removal
Description: Standard carotid endarterectomy will be extended with the stent removal
Study NCT03019185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Capsule containing an inert placebo
Study NCT03019185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl
Description: Bardoxolone methyl dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
Study NCT03019185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bardoxolone Methyl
Description: Bardoxolone methyl dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
Study NCT02791373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Mobilisation Chemotherapy
Study NCT02791373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Mobilisation Chemotherapy
Study NCT03982615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-Lok abutment
Description: Each subject will receive two dental implants. One implant will receive (by randomization) a laser-etched (Laser-Lok) abutment.
Study NCT03982615 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard healing abutment
Description: Each subject will receive two dental implants. One implant will receive (by randomization) receive a standard healing abutment (not laser-etched).
Study NCT01556893 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LenSx Laser
Description: The LenSx laser system is a femtosecond laser that has received 510(k) clearance for anterior capsulotomy during cataract surgery (K082947), laser phacofragmentation during cataract surgery (K094052) and for use in the creation of a single and multi-plane arc cut/incisions in the cornea (K092647).
Study NCT01116986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal phone counseling during the quit attempt
Description: Participants randomized to this condition will receive minimal phone counseling consisting of one 10-minute phone counseling session on the morning of the target quit day. This session will address motivation to quit, strategies for coping with urges to smoke and use of the medication, and will provide support. Thus, all participants will get some counseling support on the quit day, which reflects the fact that initial lapses often occur on the target quit day, and quit day smoking is an important determinant of ultimate outcome.